Skip to main content
SpringerLink
Log in

Pharmacokinetic and pharmacodynamic aspects of concomitant mibefradil-digoxin therapy at therapeutic doses

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

This study investigated the effect of mibefradil on digoxin pharmacokinetics an pharmacodynamics. Following a loading dose of digoxin (0.375 mg, three times, day 1), 0.375 mg was administered once daily to 40 healthy subjects (days 2–15). Mibefradil was administered daily at 50 mg, 100 mg, or 150 mg (days 9–15). With co-administration of 50 mg or 100 mg mibefradil (the recommended doses), mean digoxin Cmax values increased 1.19- and 1.32-fold, respectively; Cmin values were 0.95- and 1.04-fold, respectively; mean AUC0−24h increased 1.05- and 1.11-fold, respectively; and the total amount of digoxin excreted in urine remained unchanged. Digoxin monotherapy produced modest but transient prolongations of PQ interval, small decreases in heart rate, and no changes in blood pressure. With the addition of mibefradil, no effects on trough blood pressure or cardiac index were observed, but there was a further increase in PQ interval and decrease in heart rate. In a previous study, mibefradil had no significant effect on trough plasma digoxin concentration in patients with congestive heart failure and ischemia. Therefore, while the vast majority of patients should not need their digoxin dosages adjusted when given mibefradil, an occasional patient may require dose reductions based on clinical response and plasma digoxin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mishra S., Hermsmeyer K. (1994): Selective inhibition of T-type Ca2+ channels by Ro 40−5967. Circ. Res., 75: 144–148.

    CAS  PubMed  Google Scholar 

  2. Clozel J-P., Banken L., Osterrieder W. (1989): Effects of Ro 40–5 967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs. comparison with verapamil. J. Cardiovasc. Pharmacol., 14: 713–721.

    Article  CAS  PubMed  Google Scholar 

  3. Clozel J-P., Véniant M., Osterrieder W. (1990): The structurally novel Ca2+ channel blocker Ro 40–5967, which binds to the [3H]-desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc. Drugs Ther., 4: 731–736.

    Article  CAS  PubMed  Google Scholar 

  4. Schmitt R., Kleinbloesem, C., Belz, G.et al. (1992): Hemodynamic and humoral effects of the novel calcium antagonist Ro 40–5967 in patients with hypertension. Clin. Pharmacol. Ther., 52: 314–323.

    CAS  PubMed  Google Scholar 

  5. Bernink P., Prager G., Schelling A., Kobrin I. (1996): Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40–5967): a new generation of calcium antagonists? Hypertension, 27: 426–432.

    CAS  PubMed  Google Scholar 

  6. Bursztyn M., Kadr H., Tilvis R.et al. (1997): Mibefradil, a novel calcium antagonist, in elderly hypertensives: favorable hemodynamics and pharmacokinetics. Am. Heart J., 134: 238–247.

    Article  CAS  PubMed  Google Scholar 

  7. Carney S., Wing L., Ribeiro A.et al. (1997): The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J. Hum. Hypertens., 11: 387–393.

    Article  Google Scholar 

  8. Oparil S., Kobrin I., Abernethy D., Levine B., Reif M., Shepherd A. (1997)b: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am. J. Hypertens., 10: 735–742.

    Article  CAS  PubMed  Google Scholar 

  9. Alpert J., Kobrin I., DeQuattro V., Friedman R., Shepherd A., Fenster P. (1997): Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta-blocker for chronic stable angina pectoris. Am. J. Cardiol., 79: 1025–1030.

    Article  CAS  PubMed  Google Scholar 

  10. Bakx A., van der Wall E., Braun S., Emanuelsson H., Bruschke A., Kobrin I. (1995): Effects of the new calcium antagonist mibefradil (Ro 40–5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am. Heart J., 130: 748–757.

    Article  CAS  PubMed  Google Scholar 

  11. Braun S., van der Wall E., Emanuelsson H., Kobrin I. (1996): Effects of a new calcium antagonist, mibefradil (Ro 40–5967), on silent ischemia in patients with stable chronic angina pectoris-. a multicenter placebo-controlled study. J. Am. Coll. Cardiol., 27: 317–322.

    Article  CAS  PubMed  Google Scholar 

  12. Reuning R., Geraets D., Rocei, M., Vlasses P. (1992): Digoxin. In: Evans W., Schentag J., Jusko W. (Eds) Applied pharmacokinetics: principles of therapeutic monitoring. Vancouver: Applied Therapeutics, 20-1–20-48.

    Google Scholar 

  13. Klein H. Lang R., DiSegni E., Kaplinsky E. (1980): Verapamil-digoxin interaction. N. Engl. J. Med., 303: 160.

    CAS  PubMed  Google Scholar 

  14. Belz G., Aust P., Munkes R. (1981): Digoxin plasma concentrations and nifedipine. Lancet, 1: 844–845.

    Article  CAS  PubMed  Google Scholar 

  15. Pedersen K., Dorph-Pedersen A., Hvidt S., Klitgaard N., Kjaer K., Nielsen-Kudsk F. (1982): Effect of nifedipine on digoxin kinetics in healthy subjects. Clin. Pharmacol. Ther., 32: 562–565.

    CAS  PubMed  Google Scholar 

  16. Pederson K., Dorph-Pederson A., Hvidt S., Klitgaard N., Pederson, K. (1982): The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur. J. Clin. Pharmacol., 221: 123–127.

    Article  Google Scholar 

  17. Siepmann M., Kleinbloesem C., Kirch W. (1995): The interaction of the calcium antagonist Ro 40–5967 wity digoxin. Br. J. Clin. Pharmacol., 39: 491–496.

    CAS  PubMed  Google Scholar 

  18. Chen C., Lindberg E., Welker H., Kobrin I. (1996): Population pharmacodynamic analysis (using NONMEM) of mibefradil in patients with ischemic congestive heart failure [Abstract]. Pharm. Res., 13: S424.

    Google Scholar 

  19. Gibaldi M., Perrier D. (1982): Pharmacokinetics. New York: Marcel Dekker.

    Google Scholar 

  20. Schwartz J. (1988): Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. J. Cardiovasc. Pharmacol., 12: 1–5.

    Article  CAS  PubMed  Google Scholar 

  21. Dunselman P., Scaf A., Kuntze C., Lie K., Wesseling H. (1988): Digoxin-felodipine interaction in patients with congestive heart failure. Eur. J. Clin. Pharmacol., 35: 461–465.

    Article  CAS  PubMed  Google Scholar 

  22. Kelly R., Smith T. (1996): Pharmacological treatment of heart failure. In: Hardman J., Limbird L., Molinoff P., Ruddon R., Gilman A. (Eds) Goodman and Gilman’s: The pharmacological basis of therapeutics, 9th edn. New York. McGraw-Hill, 809–838.

    Google Scholar 

  23. Orito K., Satoh K., Taira N. (1993): Cardiovascular profile of Ro 40–5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J. Cardiovasc. Pharmacol., 22: 293–299.

    Article  CAS  PubMed  Google Scholar 

  24. Rosenquist M., Brembilla-Perrot B., Meinertz T.et al. (1997): The acute effects of intravenously administered mibefradil on the electrophysiologic characteristics of the human heart. Eur. J. Clin. Pharmacol., 52: 7–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. F. Hoffmann-La Roche, Ltd, PDC5 Bldg 52/901, CH-4002, Basel, Switzerland

    J. Peters, H. A. Welker & R. Bullingham

Authors
  1. J. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. A. Welker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Bullingham
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peters, J., Welker, H.A. & Bullingham, R. Pharmacokinetic and pharmacodynamic aspects of concomitant mibefradil-digoxin therapy at therapeutic doses. Eur. J. Drug Metab. Pharmacokinet. 24, 133–140 (1999). https://doi.org/10.1007/BF03190358

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190358

Keywords

Search

Navigation